A set of deals among several leading pharma companies is heightening the rivalry between the world's top cancer drugmakers. Novartis agreed to buy GlaxoSmithKline's line of cancer treatments for up to $16 billion, while selling it a vaccine business for as much as $7.1 billion. The deal could boost oncology sales for Novartis by almost 40 percent to $11.2 billion a year by 2018. The Swiss drug giant is No. 2 in market share for cancer drugs after Roche.
展开▼
